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and core values of our organization and is viewed as a positive force
on the unit.
263
ABC’S OF ABO–A REFRESHER FOR BLOOD AND MARROW TRANSPLANT
NURSES
Meyers, A.L. University of Texas MD Anderson Cancer Center, Hous-
ton, TX
Blood and Marrow Transplant (BMT) nurses must posses a vast
knowledge of many complicated nursing assessment skills. Sup-
portive measures that the team must institute to carry a patient
safely through this treatment regimen, include administration of
broad-spectrum antibiotics and blood products. Of the many re-
sponsibilities for BMT nurses blood administration is a major
psychomotor skill that is performed daily and often perceived as an
easy skill when in actuality it can be a very involved process. BMT
patients need a variety of blood products, including PRBC, plate-
lets, cryoprecipitate, fresh frozen plasma, and WBC’s for different
reasons and the BMT nurse must be aware of these products and
indications to use them. It is important that nurses are aware of
compatibility issues, leukocyte reduced products, irriated products,
indications for use of speciﬁc products as well as possible patient
responses to these products. It is also crucial to know the implica-
tion for BMT patients, especially in the allogeneic patients when
blood type between patient and donor may not be compatible.
Reviewing ABO and Rh compatibility information serves as a basis
for understanding the procedures and assessment that are critical
for a safe and successful transfusion. BMT patients have the added
complication of changing blood types and the BMT nurse must be
aware of this time period to deliver the safest product. Items to be
reviewed include ABO and RH typing, ABO compatibility, signs
and symptoms of transfusion reaction as well as delayed reaction,
irradiation, leukocyte reduction, donor issues, implications of
transfusion for BMT patients, and nursing care and assessment of
transfusions. An article with CEU credit will also be distributed.
Most often the care of a patient receiving a transfusion is routine
and uneventful. However, a great deal of knowledge is required
before a nurse can understand aspects of transfusion therapy and
intervene when a reaction does occur. Consistent high level nurs-
ing assessment and skills are paramount to knowing how and when
to intervene.
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NURSING MANAGEMENT OF PATIENT WITH HEMORRHAGIC CYSTITIS
POST BMT
Dela Cruz, B.P. MD Anderson Cancer Center, Houston, TX
Hemorrhagic cystitis is a syndrome of hematuria with symptoms
of urinary tract irritability indicated by dysuria, frequency and
urgency. Incidence varies according to conditioning regimen, pre-
ventative measures employed, and graft versus host disease pro-
phylaxis used. There are two types of occurrences: 1. Early onset
happens during or shortly after the conditioning regimen in which
patients may have received cyclophosphamide, ifosphamide or
busulfan. 2. Late onset occurs weeks to months after bone marrow
transplant related to contraction of certain viruses.
BMT patient who are immunocompromised, viruses are reacti-
vated and excreted in the urine. In general viral shredding occurs
2-8 weeks after BMT and resolves spontaneously within three
weeks. Another risk factor that contributes to hemorrhagic cystitis
is GVHD. The bladder epithelium is a target organ for GVHD to
attack and immunosuppressed patients already having associated
complications with GVHD have an increased risk for acquiring
viral infections.
Standard treatment modalities of hemorrhagic cystitis are: 1.
Hydrating patients with intravenous and oral ﬂuids. 2. Continuous
bladder irrigation. 3. Bladder Instillation with Alum, Carboprost,
silver nitrate, phenol, prostaglandin, and hydrocortisone. 4. Giving
smooth muscle relaxants for bladder spasms. 5. Antiviral therapy. 6.
Cystoscopy. 7. Our center is studying NOVO-seven injections to
help with the clotting mechanism.
The nurses have an essential role in early detection. Mnemonics
that would assist nurses in patient assessment is “U PAAS BI.”
U-urinary output, P-pain management, A–assessment of urine,
S–specimen collection for urine cytology, B–blood counts and
I-infusion of blood products as necessary.
Chemotherapy and viruses may account for a substantial propor-
tion of late onset and long lasting hemorrhagic cystitis in BMT
patients. In conclusion, nursing plays a huge role in prevention,
early detection and treatment of hemorrhagic cystitis.
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THERAPEUTIC MILESTONE OF DONOR LYMPHOCYTE INFUSION
Austria, M.L.R., Ramirez, M.P.T. MD Anderson Cancer Center,
Houston, TX
Since early 1990, several studies cited that transfusion of donor
lymphocytes is effective in inducing remission in patients with
relapsed hematologic malignancies after allogeneic stem cell trans-
plant. The procedure requires the leukocyte donor, which in most
cases is the original donor to undergo leukopheresis. The lympho-
cytes are then infused into the patient either immediately or after
it has been frozen. Such treatment attempts the donor’s lympho-
cytes to seek out the patient’s cancer cells and eventually destroy
them without the need for further high-dose chemotherapy or
second transplant. This beneﬁcial effect is called graft-versus-
malignancy effect.
Donor lymphocyte infusion (DLI) is used for various malignan-
cies. The majority of Chronic Myelogenous Leukemia (CML)
patients have impressive outcomes but less effective in acute leu-
kemias, myelodysplasia, multiple myeloma, Hodgkin’s disease, and
non-Hodgkin’s lymphoma. In addition, the presence of chronic
graft-versus-host disease (GVHD) after initial bone marrow trans-
plant, T-cell depletion, underlying disease and stage at relapse, and
the level of mixed chimerism inﬂuence the response rate. It works
effectively at the stage of minimum residual disease (MRD) and
should be used at the ﬁrst signs of disease recurrence (Sladen, S.).
The main causes of morbidity and treatment-related toxicities
include GVHD and bone marrow aplasia, with increased im-
munosuppression and susceptibility to opportunistic infections.
Continued research is ongoing to determine the long-term ef-
fectiveness of DLI, minimizing its side effects and the induction of
graft versus malignancy effect.
Response rate of various malignancies from DLI and a case study
will be presented.
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DEVELOPMENT OF A TRANSPLANT EDUCATIONAL PROGRAM THAT
PROVIDES CONSISTANT EDUCATION, IS AVAILABLE ON-DEMAND, AND
IS EASY TO UPDATE
Kruse, S.M., Schmit-Pokorny, K. University of Nebraska Medical Cen-
ter, Omaha, NE
Development of a professional patient education tool that pro-
vides consistent education but is easy to update has been difﬁcult
for blood and marrow stem cell transplantation (BMSCT). Many
videos exist that have been developed at a high cost. However,
videos out-date very quickly and it is impossible to ensure each
patient has the most current copy of the information.
For many years at our transplant center, the initial educational
session was 1:1 with the patient and family. The sessions provided
information on the basics of BMSCT and lasted 2-3 hours. Due to
duplication of nursing effort and lack of consistent information, a
class for BMSCT was developed in 1995. The nurse case managers
would rotate teaching the class that consisted of a slide show
presentation and an outline. There were variations and inconsis-
tencies in the information given depending on the nurses’ area of
expertise and their teaching abilities.
In 2003, a 40-minute multimedia presentation, consisting of
scripted audio speciﬁc to each corresponding visual media, and
streaming video was developed. This presentation is available to
patients and family on a ‘video on-demand service’ available in all
transplant patient suites, treatment center rooms, and other patient
care areas. The patient or caregiver can view the presentation 24
hours a day at their convenience. Over a period of seven months,
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